Grifols (GIFLF) EBIT Growth (3y) (2013 - 2025)
Powered by 
Analysis
Grifols (GIFLF) EBIT Growth (3y) (2013 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 9.40% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -102.00% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 6.70% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 8.36% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 89.72% |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 24.14% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 44.34% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -96.48% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 61.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 61.29% |
| Dec 31, 2024 | 126.04% |
| Dec 31, 2022 | -50.89% |
| Dec 31, 2021 | -36.23% |
| Dec 31, 2020 | -28.87% |
| Mar 31, 2020 | 55.09% |
| Dec 31, 2019 | 81.26% |
| Mar 31, 2019 | 54.28% |
| Dec 31, 2018 | -31.55% |
| Jun 30, 2018 | 6.44% |
| Mar 31, 2018 | 4.01% |
| Dec 31, 2017 | 6.20% |
| Jun 30, 2017 | 957.08% |
| Mar 31, 2017 | -4.26% |
| Dec 31, 2016 | 28.39% |
| Sep 30, 2016 | 2.73% |
| Jun 30, 2016 | 0.70% |
| Mar 31, 2016 | 1.05% |
| Dec 31, 2015 | 59.47% |
| Sep 30, 2015 | 8.64% |